The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs).
Jeuveau is a prescription treatment injected into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows in adults.
Regulators determined that the social media content misbrands the product by exaggerating treatment efficacy, oversimplifying drug safety risks, and improperly likening the prescription injectable to an everyday cosmetic item.
Misleading Claims On Treatment Efficacy And Speed
According to regulatory findings, social media reels published on company accounts misleadingly suggested that Jeuveau eliminates frown lines and acts in as little as two days.
The agency noted that FDA-approved clinical indications only support temporary improvement of moderate to severe glabellar lines or frown lines.
Furthermore, claims highlighting rapid two-day results relied on exploratory trial endpoints rather than statistically rigorous primary efficacy data assessed at Day 30.
The agency emphasized that combining distinct study endpoints creates a deceptive impression regarding how fast and effectively the drug performs.
A previous advisory communication sent to the firm in November 2019 had already cautioned against similar representations regarding treatment onset speed.
Downplaying Health Risks And Toxin Safety Warnings
Federal officials also raised public health concerns over how the promotional campaign presented critical safety data.
Jeuveau carries a boxed warning concerning the potential distant spread of toxin effects, along with other serious medical precautions.
During the second quarter of 2026, David Moatazedi, President and CEO of Evolus, commented, “The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau and accelerating adoption of Evolysse.
Regulatory Action And Compliance Requirements
The regulatory body warned that distributing misbranded prescription drugs violates federal law.
Regulators gave the company 15 working days to respond in writing with a comprehensive plan to discontinue violative promotional materials or cease product distribution.
EOLS Price Action: Evolus shares were down 5.92% at $7.23 at the time of publication on Friday, according to Benzinga Pro data.
Photo by Panchenko Vladimir via Shutterstock
Login to comment